Abstract
Objective. To evaluate the effectiveness and safety of S-1 monotherapy for lung cancer associated with interstitial pneumonia (IP). Methods. The medical records of 15 patients with lung cancer-associating IP from April 2005 through March 2015 were retrospectively evaluated to determine the clinical response, adverse effects, and frequency of acute respiratory deterioration after S-1 monotherapy. Results. The median age was 73 (range, 64-80) years, the male/female ratio was 13/2, and 14 patients were smokers. The Eastern Cooperative Oncology Group performance status was 0/1/2/3 in 2/5/5/3 patients, respectively. The epidermal growth factor receptor mutation status was positive, negative, and unknown in 1/9/5 patients, respectively. The histopathological type was adenocarcinoma in 8, squamous cell carcinoma in 5, and other in 2 patients. The clinical stage was I/II/IIIA/IIIB/IV/postoperative recurrence in 2, 0, 2, 3, 6, and 2 patients, respectively. S-1 monotherapy was given as first-/second-/third-/fourth-line or later chemotherapy in 3, 1, 4, and 7 patients, respectively. The IP pattern was usual IP in 11 patients and non-usual IP in 4 patients. The median number of S-1 monotherapy cycles was 2 (range, 1-6); each cycle continued for 4 weeks, followed by a 2-week rest period. The median progression-free survival after S-1 monotherapy was 71 (range, 12-293) days, and the median survival time was 329 (range, 24-1291) days. There were no cases of acute respiratory deterioration after S-1 monotherapy. Conclusion. S-1 monotherapy was safe and effective for patients with lung cancer-associating IP, including those with a poor performance status and those who had previously received multiple lines of chemotherapy.
